High-dose chemotherapy in nonseminomatous germ cell cancer

BJU International

Volumn 104, Issue 9 B, 2009, Pages 1398-1403

  Kollmannsberger, Christian ^a   Beyer, Joerg ^b   Bokemeyer, Carsten ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VIVANTES KLINIKUM AM URBAN   (Germany)

^c UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CARBOPLATIN; CHORIONIC GONADOTROPIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; IFOSFAMIDE; THIOTEPA; VINBLASTINE;

AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG MEGADOSE; HUMAN; MULTIPLE CYCLE TREATMENT; NON SEMINOMATOUS GERMINOMA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; HUMANS; IFOSFAMIDE; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; VINDESINE;

EID: 70350441764     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08866.x     Document Type: Review

References (30)

1. Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990 8 : 1777 1781
2. Mead G. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997 15 : 594 603
3. Elias A, Ayash L, Eder JP et al. A phase-I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. J Clin Oncol 1991 9 : 320 327
4. Wolff SN, Johnson DH, Hainsworth JD, Greco FA. High-dose VP-16-213 monotherapy for refractory germinal malignancies: a phase II study. J Clin Oncol 1984 2 : 271 274
5. Nichols CR, Roth BJ, Loehrer PJ, Williams SD, Einhorn LH. Salvage chemotherapy for recurrent germ cell cancer. Semin Oncol 1994 5 (Suppl. 12 102 108
6. Rick O, Siegert W, Beyer J. Chemotherapy in patients with metastatic or relapsed germ-cell tumours. Cancer Treat Rev 2001 27 : 283 288
7. Beyer J, Kramar A, Mandanas R et al. High-dose chemotherapy as salvage treatment in germ cell tumors. A multivariate analysis of prognostic variables. J Clin Oncol 1996 14 : 2638 2645 (Pubitemid 26329647)
8. Nichols CR. Treatment of recurrent germ cell tumors. Semin Surg Oncol 1999 17 : 268 274
9. Droz JP, Pico JL, Ghosn M et al. A phase II trial of early intensive chemotherapy with autologous bone marrow transplantation in the treatment of poor prognosis non seminomatous germ cell tumors. Bull Cancer 1992 79 : 497 507
10. Motzer RJ, Mazumdar M, Bajorin DF, Bosl GJ, Lyn P, Vlamis V. High- dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 1997 15 : 2546 2552
11. Schmoll HJ, Kollmannsberger C, Metzner B et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 2003 21 : 4083 4091
12. Chevreau C, Droz JP, Pico JL et al. Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomized trial. Eur Urol 1993 23 : 213 217
13. Droz JP, Kramar A, Biron P et al. Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-Volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. Eur Urol 2007 51 : 739 746
14. Motzer RJ, Mazumdar M, Gulati SC et al. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 1993 85 : 1828 1835 (Pubitemid 23333615)
15. Bokemeyer C, Kollmannsberger C, Meisner C et al. First-line high-dose chemotherapy compared to standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors. A multivariate and matched pair analysis. J Clin Oncol 1999 17 : 3450 3456
16. Motzer RJ, Nichols CJ, Margolin KA et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 2007 25 : 247 256
17. Nichols CR, Tricot G, Williams SD et al. Dose-intensive chemotherapy in refractory germ cell cancer - a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989 7 : 932 939
18. Lorch A, Kollmannsberger C, Hartmann JT et al. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol 2007 25 : 2778 2784
19. Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007 357 : 340 348
20. Kondagunta GV, Bacik J, Sheinfeld J et al. Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol 2007 25 : 85 90
21. Motzer RJ, Mazumdar M, Sheinfeld J et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 2000 18 : 1173 1180
22. Siegert W, Beyer J, Strohscheer I et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. J Clin Oncol 1994 12 : 1223 1231
23. Rodenhuis S, de Wit R, de Mulder PH et al. A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission. Ann Oncol 1999 10 : 1467 1473
24. Rick O, Bokemeyer C, Beyer J et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stell cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 2001 19 : 81 8
25. Lotz JP, Bui B, Gomez F et al. Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial. Ann Oncol 2005 16 : 411 418
26. Beyer J, Stenning S, Gerl A, Fossa S, Siegert W. High-dose versus conventional-dose chemotherapy as first-line treatment in patients with non-seminomatous germ-cell tumors: a matched pair analysis. Ann Oncol 2002 13 : 599 605
27. Pico JL, Rosti G, Kramar A et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 2005 16 : 1152 1159
28. Mead GM, Cullen MH, Huddart R et al. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer 2005 93 : 178 184
29. Bokemeyer C, Schleucher N, Metzner B et al. First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial. Br J Cancer 2003 89 : 29 35
30. Rosti G, De Giorgi U, Wandt H et al. First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party. Bone Marrow Transplant 2004 34 : 1033 1037